Roivan­t's JAK/TYK2 in­hibitor fails PhII lu­pus study

Roivant re­port­ed Mon­day morn­ing that a pro­gram li­censed from Pfiz­er failed a Phase II lu­pus tri­al and that it would end de­vel­op­ment in the con­di­tion.

The drug, known as bre­poc­i­tinib, did not achieve sta­tis­ti­cal sig­nif­i­cance in a study com­par­ing it to place­bo in adults with mod­er­ate to se­vere ac­tive lu­pus. Roivant and the “Vant” hous­ing the drug, Pri­o­vant, blamed a high place­bo rate for the flop.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER